Janux Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
MWN-AI** Summary
Janux Therapeutics, Inc. (Nasdaq: JANX) reported promising financial results for the fourth quarter and full year of 2024, along with significant business updates. The company, known for its innovative immunotherapy pipeline, displayed a strong cash position of $1.03 billion, a substantial increase from $344 million at the end of 2023. This financial strength supports its clinical development efforts and ongoing trials for its investigational drugs, JANX007 and JANX008.
In December 2024, Janux presented interim Phase 1 clinical trial data for JANX007 targeting metastatic castration-resistant prostate cancer (mCRPC), highlighting notable outcomes: a 100% rate of achieving at least a 50% reduction in PSA levels (PSA50), with 63% achieving a 90% reduction (PSA90) or greater. The therapy maintained a favorable safety profile, showcasing low-grade adverse events primarily confined to the initial treatment cycle.
The company has initiated enrollment for both JANX007 and JANX008, with additional data updates anticipated in 2025. Furthermore, an R&D Day is planned for the same year to discuss new developmental programs. Financially, Janux saw its research and development expenses rise to $20.8 million in Q4 and $68.4 million for the entire year, reflecting increased investment in clinical trials.
Despite net losses of $20.2 million for the fourth quarter and $69 million for the year, the company remains optimistic. President and CEO David Campbell emphasized the potential of their TRACTr platform and the commitment to advancing new therapeutic candidates aimed at significant patient impact. Overall, 2024 was characterized as a pivotal year for Janux, setting the stage for promising developments in the cancer treatment arena.
MWN-AI** Analysis
Janux Therapeutics’ recent financial report for Q4 and the full year 2024 has evoked heightened interest among investors, presenting a compelling case for market optimism. The company, with its pioneering TRACTr platform, showcased robust clinical trial data for its lead product, JANX007, which targets metastatic castration-resistant prostate cancer (mCRPC). With 100% of patients achieving a PSA50 decline and significant PSA90 and PSA99 responses, the data reflect substantial clinical promise that could translate into a competitive advantage in the oncology market.
The company reported a remarkable cash position of approximately $1.03 billion at the end of 2024, an increase from $344 million year-over-year, providing a solid financial runway to support ongoing and future clinical trials, including JANX008, which targets a broader range of advanced solid tumors. This strong liquidity suggests Janux is well-positioned to navigate the unpredictable nature of drug development and potential regulatory environments.
However, investors should note the increase in R&D and G&A expenses, which reflects the company’s proactive approach to expanding its clinical pipeline and operational capabilities. The net loss for the year also widened to $69 million, although this was anticipated given the scale of their clinical endeavors.
Looking ahead, Janux’s scheduled R&D Day in 2025 promises to unveil additional programs and results from both JANX007 and JANX008, which could further fuel investor enthusiasm and market traction.
In conclusion, investors considering Janux Therapeutics might view the current landscape as an attractive entry point, given the strong financial backing, encouraging clinical outcomes, and the prospects of new therapeutic developments. Caution should be exercised regarding the inherent risks of clinical trials and market fluctuations; however, the emerging value proposition in their therapeutic advancements suggests potential for long-term growth.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
- Recently presented positive Phase 1 clinical trial data for PSMA-TRACTr JANX007 in mCRPC
- Enrollment ongoing for JANX007 and JANX008
- Update on JANX007 and JANX008 data is anticipated in 2025
- R&D Day is anticipated in 2025 to disclose new programs moving toward the clinic
- $1.03 billion in year-end cash, cash equivalents, and short-term investments
Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.
“2024 was an exceptional year for Janux as we displayed the potential power of our TRACTr platform in the clinic. We believe the data recently presented from JANX007 demonstrated substantial clinical activity in late line mCRPC patients, supporting our future clinical development plans directed at earlier line patients. With our substantial cash runway, we feel well-positioned to execute on our clinical plans, as well as bring new programs towards the clinic that could provide substantial value to both Janux, and more importantly, the patients we serve,” said David Campbell, Ph.D., President and CEO of Janux.
RECENT BUSINESS HIGHLIGHTS AND FUTURE MILESTONES:
- Presented positive updated interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer in December 2024. As of the November 15, 2024, data cutoff in 16 patients JANX007 displayed:
- High prostate-specific antigen (PSA) response rates: 100% achieved best PSA50 declines.
- Deep PSA declines: 63% achieved best PSA90 declines; 31% achieved best PSA99 declines.
- Durable PSA declines maintained at ? 12 weeks: 75% maintained PSA 50 declines; 50% maintained PSA90 declines.
- Encouraging anti-tumor activity: 50% ORR (4/8) and 63% DCR (5/8) (including confirmed and unconfirmed).
- Well-tolerated safety profile: CRS and TRAEs primarily limited to cycle 1 and lower grades.
- Gross proceeds of approximately $402.5 million (before deducting underwriting discounts and commissions and other estimated offering expenses) raised in an underwritten offering of common stock and pre-funded warrants in December 2024.
- Janux to host R&D Day in 2025.
- Janux plans to provide an update on pipeline programs selected for clinical development.
- JANX007 continues to enroll in the first-in-human Phase 1 clinical trial in mCRPC (NCT05519449).
- JANX008 continues to enroll in the first-in-human Phase 1 clinical trial in advanced or metastatic solid tumors (NCT05783622).
- Zachariah McIver, D.O., Ph.D. promoted to Chief Medical Officer. Dr. McIver has been instrumental in executing on Janux’s clinical programs. Dr. McIver continues to lead cross-functional teams in the design, implementation, and execution of clinical and correlative study strategies. An accomplished physician-scientist with over 15-years of experience in clinical research, Dr. McIver joined Janux after serving as Amgen’s Executive Medical Director for over 4 years.
An update on JANX007 and JANX008 data is anticipated in 2025. Janux will also be hosting an R&D Day in 2025.
FOURTH QUARTER AND FULL YEAR 2024 FINANCIAL RESULTS:
- Cash and cash equivalents and short-term investments: As of December 31, 2024, Janux reported cash and cash equivalents and short-term investments of $1.03 billion compared to $344.0 million at December 31, 2023.
- Research and development expenses: Research and development expenses were $20.8 million for the quarter and $68.4 million for the year ended December 31, 2024, compared to $12.2 million and $54.9 million for the same quarter and year in 2023.
- General and administrative expenses: General and administrative expenses were $8.2 million for the quarter and $41.0 million for the year ended December 31, 2024, compared to $6.4 million and $26.1 million for the same quarter and year in 2023.
- Net loss: Net loss was $20.2 million for the quarter and $69.0 million for the year ended December 31, 2024, compared to $11.8 million and $58.3 million for the same quarter and year in 2023.
Janux’s TRACTr and TRACIr Pipeline
Janux’s first clinical candidate, JANX007, is a TRACTr that targets prostate-specific membrane antigen (PSMA) and is being investigated in a Phase 1 clinical trial in adult patients with metastatic castration-resistant prostate cancer (mCRPC). Janux’s second clinical candidate, JANX008, is a TRACTr that targets epidermal growth factor receptor (EGFR) and is being studied in a Phase 1 clinical trial for the treatment of multiple solid cancers including colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. We are also generating a number of additional TRACTr and TRACIr programs for potential future development, some of which are at development candidate stage or later. We are currently assessing priorities in our preclinical pipeline.
About Janux Therapeutics
Janux is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Janux’s proprietary technology enabled the development of two distinct bispecific platforms: TRACTr and TRACIr. The goal of both platforms is to provide cancer patients with safe and effective therapeutics that direct and guide their immune system to eradicate tumors while minimizing safety concerns. Janux is currently developing a broad pipeline of TRACTr and TRACIr therapeutics directed at several targets to treat solid tumors. Janux has two TRACTr therapeutic candidates in clinical trials, the first targeting PSMA is in development for prostate cancer, and the second targeting EGFR is being developed for colorectal carcinoma, squamous cell carcinoma of the head and neck, non-small cell lung cancer, renal cell carcinoma, small cell lung cancer, pancreatic ductal adenocarcinoma and triple-negative breast cancer. For more information, please visit www.januxrx.com and follow us on LinkedIn.
Forward-Looking Statements
This news release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. Such forward-looking statements include statements regarding, among other things, Janux’s ability to bring new treatments to cancer patients in need, expectations regarding the timing, scope and results of Janux’s development activities, including its ongoing and planned preclinical studies and clinical trials, the timing of and plans for regulatory filings, the potential benefits of Janux’s product candidates and platform technologies, expectations regarding the use of Janux’s platform technologies to generate novel product candidates and the strength of Janux’s balance sheet and the adequacy of cash on hand. Factors that may cause actual results to differ materially include the risk that compounds that appear promising in early research do not demonstrate safety and/or efficacy in later preclinical studies or clinical trials, the risk that Janux may not obtain approval to market its product candidates, uncertainties associated with performing clinical trials, regulatory filings and applications, risks associated with reliance on third parties to successfully conduct clinical trials, the risks associated with reliance on outside financing to meet capital requirements, and other risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. You are urged to consider statements that include the words “may,” “will,” “would,” “could,” “should,” “believes,” “estimates,” “projects,” “promise,” “potential,” “expects,” “plans,” “anticipates,” “intends,” “continues,” “designed,” “goal,” or the negative of those words or other comparable words to be uncertain and forward-looking. For a further list and description of the risks and uncertainties Janux faces, please refer to Janux’s periodic and other filings with the Securities and Exchange Commission, which are available at www.sec.gov . Such forward-looking statements are current only as of the date they are made, and Janux assumes no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.
Janux Therapeutics, Inc. | |||||||
December 31, | |||||||
Assets | 2024 | 2023 | |||||
Current assets: | |||||||
Cash and cash equivalents | $ | 430,605 | $ | 19,205 | |||
Short-term investments | 594,568 | 324,823 | |||||
Prepaid expenses and other current assets | 8,493 | 5,213 | |||||
Total current assets | 1,033,666 | 349,241 | |||||
Restricted cash | 816 | 816 | |||||
Property and equipment, net | 4,864 | 7,003 | |||||
Operating lease right-of-use assets | 19,286 | 20,838 | |||||
Other long-term assets | 2,884 | 2,509 | |||||
Total assets | $ | 1,061,516 | $ | 380,407 | |||
Liabilities and Stockholders’ Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 4,026 | $ | 2,424 | |||
Accrued expenses | 11,684 | 7,387 | |||||
Current portion of deferred revenue | — | 1,705 | |||||
Current portion of operating lease liabilities | 1,749 | 1,517 | |||||
Total current liabilities | 17,459 | 13,033 | |||||
Operating lease liabilities, net of current portion | 21,276 | 23,025 | |||||
Total liabilities | 38,735 | 36,058 | |||||
Total stockholders’ equity | 1,022,781 | 344,349 | |||||
Total liabilities and stockholders’ equity | $ | 1,061,516 | $ | 380,407 |
Janux Therapeutics, Inc. | ||||||||||||||||
Three Months Ended | Year Ended | |||||||||||||||
2024 | 2023 | 2024 | 2023 | |||||||||||||
Collaboration revenue | $ | — | $ | 2,461 | $ | 10,588 | $ | 8,083 | ||||||||
Operating expenses: | ||||||||||||||||
Research and development | 20,806 | 12,241 | 68,388 | 54,922 | ||||||||||||
General and administrative | 8,216 | 6,357 | 41,047 | 26,140 | ||||||||||||
Total operating expenses | 29,022 | 18,598 | 109,435 | 81,062 | ||||||||||||
Loss from operations | (29,022 | ) | (16,137 | ) | (98,847 | ) | (72,979 | ) | ||||||||
Total other income | 8,806 | 4,379 | 29,853 | 14,686 | ||||||||||||
Net loss | $ | (20,216 | ) | $ | (11,758 | ) | $ | (68,994 | ) | $ | (58,293 | ) | ||||
Other comprehensive gain (loss): | ||||||||||||||||
Unrealized gain (loss) on available-for-sale securities, net | (5,668 | ) | 1,840 | 1,498 | 2,200 | |||||||||||
Comprehensive loss | $ | (25,884 | ) | $ | (9,918 | ) | $ | (67,496 | ) | $ | (56,093 | ) | ||||
Net loss per common share, basic and diluted | $ | (0.36 | ) | $ | (0.25 | ) | $ | (1.28 | ) | $ | (1.32 | ) | ||||
Weighted-average shares of common stock outstanding, basic and diluted | 56,832,374 | 46,683,613 | 53,751,480 | 44,016,283 |
View source version on businesswire.com: https://www.businesswire.com/news/home/20250227733415/en/
Investors:
Andy Meyer
Janux Therapeutics
ameyer@januxrx.com
(202) 215-2579
Media:
Jessica Yingling, Ph.D.
Little Dog Communications Inc.
jessica@litldog.com
(858) 344-8091
FAQ**
How does Janux Therapeutics Inc. (JANX) plan to utilize the approximately $1.03 billion in cash reserves to advance its clinical trials and R&D initiatives over the next few years?
What specific milestones is Janux Therapeutics Inc. (JANX) aiming to achieve in its ongoing Phase 1 clinical trials for JANX007 and JANX008 by 2025?
Given the promising Phase 1 clinical trial data for JANX007, how does Janux Therapeutics Inc. (JANX) plan to address the potential for expanding its indication beyond late-line mCRPC patients?
What strategies does Janux Therapeutics Inc. (JANX) have in place to mitigate risks associated with drug development, especially in light of ongoing Phase 1 trials and the upcoming R&D Day in 2025?
**MWN-AI FAQ is based on asking OpenAI questions about Janux Therapeutics Inc. (NASDAQ: JANX).
NASDAQ: JANX
JANX Trading
-0.68% G/L:
$14.64 Last:
514,387 Volume:
$14.74 Open:
